今日盘中，晶泰控股（02228.HK）股价大涨15.28%，截至上午10:32，报价9.47港元，成交额超过22亿港元，引发市场广泛关注。
此轮涨势主要源于晶泰控股发布的积极盈利预告。公司预计2025年上半年综合收益将不少于5亿元人民币，同比增长至少387%。更值得注意的是，晶泰控股预期将首次实现半年盈利，净利润预计不少于5,000万元人民币，这标志着公司财务状况的显著改善。
晶泰控股的业绩飞跃主要得益于其与美国生物制药公司DoveTree的战略合作。今年6月，双方签署了合作协议，晶泰控股将利用其端到端人工智能药物发现平台及综合"AI+机器人"技术，为DoveTree开发肿瘤、免疫炎症等领域的候选药物。据悉，晶泰控股已于8月5日收到5100万美元的首付款，未来还有机会获得高达58.9亿美元的里程碑付款及销售分成。这一合作不仅为晶泰控股带来了可观的即时收益，也为其长期发展奠定了基础，进一步增强了投资者对公司未来前景的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.